Clinical Trial

The Effect of Glucagon on Cerebral Glucose Metabolism in Healthy Humans

Study acronym: GluCoMet_CD

Active, Not Recruiting

Record status

This record was last updated April 29, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

Summary

This is a pilot study in which the investigators will investigate the effect of exogenous glucagon on cerebral glucose metabolism in healthy humans. Participants will participate in either part C or part D of the study, and each participant will participate in three study days. During a study day the participant will receive an intravenous infusion of either glucagon, glucose (in an adjustable rate to match to glucose concentrations achieved with the glucagon infusion) or saline. During each study day an 18F-flouro-deoxy-glucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) scan will be performed to quantify cerebral glucose metabolism during the first part (acute effect) of the glucagon/glucose/saline infusion (part C) or the last part (later effect) of the glucagon/glucose/saline infusion (part D).

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-03-10; most recent amendment 2026-04-28.

Status change: Not Yet Recruiting → Active, Not Recruiting 2026-04-28

Trial Details

NCT Number	NCT06877208
Lead Sponsor	Nicolai Jacob Wewer Albrechtsen Collaborators: University Hospital Bispebjerg and Frederiksberg
Conditions	Cerebral Glucose Metabolism
Enrollment	12 participants
Start Date	2025-03-18
Primary Completion	2026-05 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2026-04-29